Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Up 66.7% in June

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) was the recipient of a large growth in short interest in June. As of June 15th, there was short interest totalling 6,000 shares, a growth of 66.7% from the May 31st total of 3,600 shares. Based on an average daily trading volume, of 128,100 shares, the short-interest ratio is currently 0.0 days.

Chugai Pharmaceutical Stock Performance

Chugai Pharmaceutical stock traded down $0.32 during trading on Friday, reaching $17.77. The company had a trading volume of 170,764 shares, compared to its average volume of 68,626. The firm’s 50-day simple moving average is $15.89 and its 200 day simple moving average is $17.89. The firm has a market capitalization of $58.46 billion, a PE ratio of 26.13 and a beta of 0.82. Chugai Pharmaceutical has a 1-year low of $13.26 and a 1-year high of $22.61.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Wednesday, April 24th. The company reported $0.15 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 31.49% and a return on equity of 20.44%. The business had revenue of $1.60 billion for the quarter. Analysts anticipate that Chugai Pharmaceutical will post 0.7 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.